79,751 Shares in InMode Ltd. (NASDAQ:INMD) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 79,751 shares of the healthcare company's stock, valued at approximately $1,332,000. Raymond James Financial Inc. owned 0.11% of InMode at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new stake in shares of InMode during the fourth quarter worth about $87,000. Farther Finance Advisors LLC raised its holdings in shares of InMode by 26.2% during the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after acquiring an additional 1,154 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of InMode in the fourth quarter valued at approximately $114,000. WINTON GROUP Ltd acquired a new stake in shares of InMode in the fourth quarter worth approximately $174,000. Finally, HighTower Advisors LLC purchased a new stake in shares of InMode during the fourth quarter worth approximately $180,000. Hedge funds and other institutional investors own 68.04% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. BTIG Research cut shares of InMode from a "buy" rating to a "neutral" rating in a research note on Tuesday, April 29th. Canaccord Genuity Group cut their price objective on shares of InMode from $17.00 to $15.00 and set a "hold" rating for the company in a report on Tuesday, April 29th. UBS Group lowered their target price on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Barclays reduced their price objective on InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Finally, Jefferies Financial Group lowered their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, InMode presently has a consensus rating of "Hold" and a consensus price target of $18.54.

InMode Trading Down 0.5 %

Shares of NASDAQ INMD traded down $0.08 during trading hours on Wednesday, reaching $14.22. The stock had a trading volume of 1,009,737 shares, compared to its average volume of 1,188,089. The firm has a 50-day moving average of $16.71 and a 200-day moving average of $17.52. The firm has a market cap of $989.34 million, a price-to-earnings ratio of 6.05 and a beta of 2.02. InMode Ltd. has a fifty-two week low of $13.68 and a fifty-two week high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). The business had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. InMode had a net margin of 45.91% and a return on equity of 18.25%. InMode's quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 earnings per share. On average, equities analysts predict that InMode Ltd. will post 1.75 EPS for the current year.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.